An injection of nanoparticles can prevent the body’s immune system from overreacting to trauma, potentially preventing some spinal cord injuries from resulting in paralysis. The approach was demonstrated in mice at the University of Michigan, with the nanoparticles enhancing healing by reprogramming the aggressive immune cells.
Call it an EpiPen for trauma to the central nervous system, which includes the brain and spinal cord.
“In this work, we demonstrate that instead of overcoming an immune response, we can co-opt the immune response to work for us to promote the therapeutic response,” said Lonnie Shea, the Steven A. Goldstein Collegiate Professor of Biomedical Engineering.
Trauma of any kind kicks the body’s immune response into gear. In a normal injury, immune cells infiltrate the damaged area and clear debris to initiate the regenerative process.
The central nervous system, however, is usually walled off from the rough-and-tumble of immune activity by the blood-brain barrier. A spinal cord injury breaks that barrier, letting in overzealous immune cells that create too much inflammation for the delicate neural tissues. That leads to the rapid death of neurons, damage to the insulating sheaths around nerve fibers that allow them to send signals, and the formation of a scar that blocks the regeneration of the spinal cord’s nerve cells.
All of this contributes to the loss of function below the level of the injury. That spectrum includes everything from paralysis to a loss of sensation for many of the 12,000 new spinal injury patients each year in the United States.
Previous attempts to offset complications from this immune response included injecting steroids like methylprednisolone. That practice has largely been discarded since it comes with side effects that include sepsis, gastrointestinal bleeding and blood clots. The risks outweigh the benefits.
But now, U-M researchers have designed nanoparticles that intercept immune cells on their way to the spinal cord, redirecting them away from the injury. Those that reach the spinal cord have been altered to be more pro-regenerative. With no drugs attached, the nanoparticles reprogram the immune cells with their physical characteristics: a size similar to cell debris and a negative charge that facilitates binding to immune cells through scavenger receptors. In theory, their non-pharmaceutical nature avoids unwanted side effects.
With fewer immune cells at the trauma location, there is less inflammation and tissue deterioration. Second, immune cells that do make it to the injury are less inflammatory and more suited to supporting tissues that are trying to grow back together.
“An immunomodulatory approach may have applications to other inflammation-mediated diseases,” said Jonghyuck Park, a U-M research fellow working with Shea. “Hopefully, this technology could lead to new therapeutic strategies not only for patients with spinal cord injury but for those with various inflammatory diseases.”
Hopefully, this technology could lead to new therapeutic strategies not only for patients with spinal cord injury but for those with various inflammatory diseases.Jonghyuck Park
U-M’s research team sees potential for the use of nanoparticles in a variety of situations dealing with the body’s immune response to trauma or cases of immune impairment. Previous research has shown success for nanoparticles mitigating trauma caused by the West Nile virus and multiple sclerosis.
“The immune system underlies autoimmune disease, cancer, trauma, regeneration… nearly every major disease,” said Shea. “Tools that can target immune cells and reprogram them to a desired response has numerous opportunities for treating or managing disease.”
The paper, titled “Intravascular innate immune cells reprogrammed via intravenous nanoparticles to promote functional recovery after spinal cord injury,” was recently published in the journal Proceedings of the National Academy of Sciences of the United States of America.
This research was supported by The National Institutes of Health.
Lonnie Shea is also the William and Valerie Hall Chair of Biomedical Engineering, and a professor of chemical engineering.